The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.
Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.
Some of our industry partners. We are delighted to have established partnerships with prominent pharmaceutical companies that have adopted our Dispersome® Technology. These valued collaborations underscore our commitment to advancing drug solubility, positively impacting patient well-being, and shaping the future of drug delivery.
September 1, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has strengthened its management team with the appointment of Dr. Mads Aaboe Jensen as Vice President Business
June 8, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and ...
AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop